For those members who have an advanced understanding of MDS, there is a recent OncologySTAT posting update of "New Therapeutics for Myelodysplastic Syndromes" that has FREE ACCESS today to Leukemia Research...
http://www.oncologystat.com/journals...Syndromes.html
A few words of caution: Free Access may be withdrawn at any time; the depth of descriptions may be too technical for some members/guests.
A copy of the summary (below) provides an idea of level for understanding the full article.
"While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinical development, many of which were not discussed in this review. Nevertheless, our paradigm for the approach to treatment of MDS can be expected to evolve with our ever expanding insight into the disease biology, targeting not only the MDS clone, but also the surrounding microenvironment while at the same time considering the context of the dynamics of disease pathogenesis."
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%
)
47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
Mon Sep 24, 2012, 09:28 PM
Similar Threads
